UCB

UCB (EBR:UCB) UCB entitled to receive milestone payment and royalties from Pfizer

UCB (EBR:UCB) * UCB on track to achieve 2008 and 2009 financial outlook * Three new drug launches in nine months * Continued roll-out of strategy * Early research with two new external partnerships

UCB (EBR:UCB) Patients treated with Cimzia®, together with methotrexate (MTX), experienced a rapid and clinically significant improvement in physical function, pain and fatigue as early as week one.

UCB (EBR:UCB) * New antiepileptic drug with a novel mechanism of action * Vimpat® helped people with epilepsy who still had uncontrolled partial onset seizures with current treatment * Vimpat® will be available in the U.S. as oral tablets and intravenous (IV) infusion * Vimpat® should be launched in the U.S. early 2009 by the well-established UCB epilepsy team

UCB (EBR:UCB) Brussels, BELGIUM, September 25, 2008 at 06:00 pm CET - press release, regulated information: UCB announced today that it is withdrawing the European Marketing Authorisation Application with the European Medicines Agency (EMEA) for Vimpat® (lacosamide) in the treatment of diabetic neuropathic pain.

UCB (EBR:UCB) * Mark McDade appointed Executive Vice President Global Operations succeeding Bill Robinson, to retire

UCB (EBR:UCB) * As adjunctive therapy, Keppra XR(TM) offers significant partial onset seizure reduction, proven tolerability, and once-daily dosing

UCB (EBR:UCB) Brussels, Belgium, September 12, 2008 - 6:00 pm CET -press release, regulated information - According to article 29 of the law of 2 May 2007 on the disclosure of major holdings, UCB releases the following information:

UCB (EBR:UCB) First New Epilepsy Treatment for Partial-Onset Seizures in Three Years

UCB (EBR:UCB) UCB has launched "SHAPE", a major global project to realize its transformation into a focused specialist company in CNS (Central Nervous System) and immunology disease areas. By this project, UCB aims to increase focus on its core assets, re-deploy its resources, advance R&D and simplify its organisation, while successfully delivering UCB's new medicines to patients. SHAPE should lead to re-allocation of EUR 300 million within the next three years, improving both competitiveness and profitability. As part of SHAPE, UCB intends to reduce its workforce by 2000 positions throughout the world, representing approximately 17% of its world-wide workforce.